CHOSA Oncology AB Logo

CHOSA Oncology AB

CHOSA | SPGR

Overview

Corporate Details

ISIN(s):
SE0007784319
LEI:
5493002SFL9YXB0A0027
Country:
Sweden
Address:
C/O Medicon Village, C/O Medicon Village, Scheeletorget 1, 223 81 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

CHOSA Oncology AB is a clinical-stage biotechnology company focused on developing solutions for precision oncology. The company's main assets are Platin-DRP™ and LiPlaCis®. Platin-DRP™ is a patented diagnostic tool that analyzes a 205-gene signature in a patient's tumor to predict their response to platinum-based chemotherapies, such as cisplatin and carboplatin. This enables personalized treatment plans, aiming to improve survival rates and avoid overtreatment. LiPlaCis® is a novel drug formulation that delivers cisplatin within a specialized liposome, designed to target tumors directly and reduce harmful side effects. CHOSA's business strategy includes forming partnerships and sublicensing agreements to advance the clinical development and commercialization of its products for cancer patients worldwide.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for CHOSA Oncology AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CHOSA Oncology AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CHOSA Oncology AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN